سعر اترافنجكس 100مجم 15 كبسولة 2025

Itraconazole 100 mg oral capsules, a systemic triazole antifungal used for nail fungal infections and systemic mycoses.

• Blastomycosis (pulmonary and extrapulmonary) and histoplasmosis (including chronic cavitary pulmonary disease and disseminated non-meningeal disease) in immunocompromised and non-immunocompromised patients.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Aspergillosis (pulmonary and extrapulmonary) in patients intolerant of or refractory to amphotericin B.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Onychomycosis of the toenail (with or without fingernail involvement) and of the fingernail caused by dermatophytes, in non-immunocompromised patients.Population: Non-immunocompromised adultsDailyMed (U.S. National Library of Medicine)

• Commonly reported reactions include headache, rash, gastrointestinal effects (nausea, diarrhoea, abdominal pain, dyspepsia), oedema and raised liver enzymes.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Do not use for onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure or a history of CHF.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Co-administration with certain CYP3A4 substrates is contraindicated because of increased plasma concentrations and risk of serious reactions (e.g. QT prolongation, torsades de pointes): including methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids, irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, lovastatin and simvastatin (see the full label list).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Do not use for onychomycosis in pregnant women or women contemplating pregnancy; known hypersensitivity to itraconazole.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: can cause or worsen congestive heart failure (negative inotropic effect); stop if signs of CHF occur. Serious drug interactions with CYP3A4 substrates can cause QT prolongation and ventricular tachyarrhythmias including torsades de pointes.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Rare cases of serious hepatotoxicity, including liver failure and death, have occurred; monitor liver function and stop if hepatic dysfunction develops.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CYP3A4 substrates (e.g. simvastatin, lovastatin, midazolam, triazolam, pimozide, quinidine, dofetilide)Itraconazole is a strong CYP3A4 inhibitor and raises their concentrations; several are contraindicated (QT prolongation, rhabdomyolysis, prolonged sedation).DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin)May greatly reduce itraconazole concentrations and efficacy; co-administration is not recommended.DailyMed (U.S. National Library of Medicine)

• Teratogenic in rats and mice at high doses; use for systemic fungal infections in pregnancy only if the benefit outweighs the potential risk; do not use for onychomycosis in pregnancy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Itraconazole is excreted in human milk; weigh the benefit of treatment against the risk to the infant.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Itraconazole: Triazole antifungal; inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase (ergosterol synthesis); also a strong inhibitor of CYP3A4, P-glycoprotein and BCRP.